Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Immunocore Holdings plcIMCR · Entity 4544 | Director | May 27, 2026 | May 28, 2026 |
| PFIZER INCPFE · Entity 2863 | Executive Vice President | March 31, 2023 | April 03, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Immunocore Holdings plc
Report date May 27, 2026 · Filed May 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.52 · Expires 2036-05-26 | Direct | 27,492 |
Reported balance
After 2026-05-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-27 · Grant · Acquired 27,492 · Balance 27,492 F1: The shares subject to the option award shall vest at the earlier of (i) May 27, 2027 and (ii) the day immediately prior to the date of the Issuer's next annual general meeting, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option award shall vest at the earlier of (i) May 27, 2027 and (ii) the day immediately prior to the date of the Issuer's next annual general meeting, subject to the Reporting Person's continuous service through such vesting date.
PFIZER INC
Report date March 31, 2023 · Filed April 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 97,765 |
Reported balance
After 2023-03-31 transaction · row 1
1 source rowRow 1 · 2023-03-31 · Tax withholding · Disposed 22,095 · Balance 97,765 F1: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon). |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 27, 2026 Filed May 28, 2026 23:55 UTC | Immunocore Holdings plc IMCR · Entity 4544 | GrantShare Option (Right to Buy) · Derivative | 27,492 | $0.00 Strike: $28.52 | $0.00 |
DisclosureSEC source: 0001919343-26-000002 · form4-05282026_070507.xml · derivative · entry 1 Pao William · CIK 0001919343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,492 Underlying: Ordinary Shares · 27,492 shares Expires 2036-05-26 F1 · derivative.exercise_date: The shares subject to the option award shall vest at the earlier of (i) May 27, 2027 and (ii) the day immediately prior to the date of the Issuer's next annual general meeting, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:15 UTC | Immunocore Holdings plc IMCR · Entity 4544 | GrantShare Option (Right to Buy) · Derivative | 26,198 | $0.00 Strike: $29.06 | $0.00 |
DisclosureSEC source: 0001415889-25-013626 · form4-05192025_040512.xml · derivative · entry 1 Pao William · CIK 0001919343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,198 Underlying: Ordinary Shares · 26,198 shares Expires 2035-05-14 F1 · derivative.exercise_date: The shares subject to the option award shall vest at the earlier of (i) May 15, 2026 and (ii) the day immediately prior to the date of our next annual general meeting, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 21:31 UTC | Immunocore Holdings plc IMCR · Entity 4544 | GrantShare Option (Right to Buy) · Derivative | 24,443 | $0.00 Strike: $29.21 | $0.00 |
DisclosureSEC source: 0001415889-25-005857 · form4-02272025_090204.xml · derivative · entry 1 Pao William · CIK 0001919343 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,443 Underlying: Ordinary Shares · 24,443 shares Expires 2035-02-24 F1 · derivative.exercise_date: This option vests in equal monthly installments over a three-year period measured from one month following February 25, 2025, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| March 31, 2023 Filed Apr 3, 2023 22:23 UTC | PFIZER INC PFE · Entity 2863 | Tax withholdingCommon Stock | 22,095 | $40.80 | $901,476.00 |
DisclosureSEC source: 0001225208-23-004397 · doc4.xml · nonDerivative · entry 1 Pao William · CIK 0001919343 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,765 F1 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon). Read SEC document |
| February 23, 2023 Filed Feb 25, 2023 01:58 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 69,938 | $0.00 Strike: $42.30 | $0.00 |
DisclosureSEC source: 0001225208-23-002817 · doc4.xml · derivative · entry 3 Pao William · CIK 0001919343 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,938 Underlying: Common Stock · 69,938 shares Expires 2030-02-23 F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 23, 2023 Filed Feb 25, 2023 01:58 UTC | PFIZER INC PFE · Entity 2863 | GrantStock Appreciation Rights · Derivative | 80,360 | $0.00 Strike: $42.30 | $0.00 |
DisclosureSEC source: 0001225208-23-002817 · doc4.xml · derivative · entry 2 Pao William · CIK 0001919343 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,360 Underlying: Common Stock · 80,360 shares Expires 2028-02-23 F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 19:43 UTC | PFIZER INC PFE · Entity 2863 | GrantCommon Stock | 115,897 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-005294 · doc4.xml · nonDerivative · entry 1 Pao William · CIK 0001919343 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,897 F1 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.